Complications of Proton Pump Therapy 💊 One of the best figures I’ve seen in a long time. On your next ward round or in the clinic think about whether your patient really needs to be on a PPI. #GITwitter #livertwitter #gutmicrobiome #AMR https://t.co/NwOXRpSPhg

Explore the expanding role of immunotherapy in HCC 📜 Tap image to see the flashcard! Find out more about combining locoregional & systemic treatments in intermediate hepatocellular carcinoma (HCC) --> From Prof. @RuthHe12 & Prof. @BeauToskichMD Endorsed by @dice_europe

Demonstration of the Danis stent for refractory bleeding from oesophageal varices #UEGWeek

New online! Defining the mucosal ecosystem: epithelial–mesenchymal interdependence in gastrointestinal health and disease https://t.co/NMxUw2CMDi

📄 #HCC Risk in #NA-Suppressed #CHB Patients 📉 NA therapy reduces but doesn’t eliminate HCC risk 🧪 Identifies key predictors for residual risk 🩺 Supports personalized #surveillance strategies 🔗 [ https://t.co/gIzCGPZ1T7] #HCC #HepatitisB #LiverCancer #Oncology #Hepatology

🔥 Hot off the press 🔥 Do not miss out on this state of the art review on diagnostic approaches to HE written by international heavyweights in the field 🥊 🧠 . Thanks @DebbieShawcros1 @MontagneseSara and team. This is part 1 of 4, so watch this space 👀 🤯 !

🚨GI/Hep Fellowships start next week‼️ @HepCommJournal has the 📑 you need to thrive 💫 #GIHepFellowshipBootcamp First up, you get a consult for a #LiverMass, ✅ out this review about benign liver masses❕ 📍Hemangiomas 📍FNH 📍Hepatic Adenomas 📍Cysts https://t.co/4UEGFrMO8U

Original Articel Liver transplantation for primary and secondary liver tumors: Patient-level meta-analyses compared to UNOS conventional indications Ciria et al. #LiverX https://t.co/Y4iaZHnjRf

❗Altered liver sinusoidal endothelial cells in #MASLD and their evolution following lanifibranor treatment 🔓#OpenAccess at 👉 https://t.co/zpwAqq9kXt #LiverX #LiverTwitter @RautouE @FrancqueSven

The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers 💥Great review (Note: Medical writing support by Edra S.p.A. & AstraZeneca!) https://t.co/0n5XM2JJ56

Original Article Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis Souza et al. @DrLoomba #LiverX

🔥off the press: Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up @Annals_Oncology https://t.co/k6kr7AaBpT 👉get the lastest update on HCC management 👉Multiple options > MDT is key @myESMO @EASLedu @ILCAnews #livertwitter

Evolution of Therapy in Autoimmune Hepatitis. 🔓 https://t.co/aIlVVDzFI8 #AIH #LiverTwitter #OpenAccess

Pregnancy and the liver A masterclass by @MussaratRahim in @TheLancet 1. Comorbid disease 2. Liver disease caused by pregnancy 3. Drug safety 4. Ongoing trials

@drkeithsiau Zones & Patterns of Liver Injury Zone 1 (ALT > AST) ▪️Autoimmune hepatitis ▪️Viral hepatitis Zone 3 (AST > ALT + ⬆️ LDH) ▪️Ischemia ▪️Toxic events ▪️Heart failure ▪️Budd-Chiari syndrome Note: ALP is predominant in basolateral membrane https://t.co/M0Am4QmimP

Tips on how to read a paper 📚💡

ITT outcomes of pts with HCC receiving immunotherapy before liver transplant @JHepatology https://t.co/Y9gBUv8n0G 🔎🇺🇸VITALITY study 👉86 pts 👉75.6% downstaged 👉36% LTx 👉3-year ITT OS 71.1% 👉 7 rejections, 1 graft lost 🧐More evidence to support ICI before LTx @myESMO

New guidelines for MASLD @JHepatology 📌 1️⃣ New classification system 2️⃣ Differential diagnoses 3️⃣ Lifestyle management 4️⃣ Medical management https://t.co/pyhgNnutR1

Causes of Portal Hypertension

Look at that beautiful ZERO..no HIV transmissions in over 2000 women who had a twice yearly injection of Lenacapavir. Is this is how we are finally going to end the HIV pandemic? Here's the full paper https://t.co/NWWt0djpaA